MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test ...

MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate ...

MINNEAPOLIS, April 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection ...

MINNEAPOLIS, May 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...

IRVINE, CA, and HERSTAL, BELGIUM – September 15, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the closing ...

Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing Prostate cancer ...

MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate ...

Bio-Techne had a good quarter overall and remains on track to exceed $1 billion of sales this year. We are leaving our $320 fair value estimate and narrow moat ratings in place as quarterly results ...

Major automakers can deal with President Donald Trump's tariffs on U.S. auto imports in a number of ways, but all of them lead to higher prices, fewer choices of models or limits on features for ...